MedPath

Boehringer Ingelheim USA Corporation

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Efficacy and Safety of Meloxicam Suspension Versus Diclofenac Suspension or Nimesulide Suspension in Patients With a Diagnosis of Acute, Non-bacterial Pharyngitis, Pharyngotonsillitis or Laryngitis

Phase 4
Completed
Conditions
Pharyngitis
Interventions
First Posted Date
2014-09-01
Last Posted Date
2014-09-01
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
128
Registration Number
NCT02229747

Safety/Tolerability, Pharmacokinetics, and Pharmacodynamics of BIBB 1464 MS in Healthy Male Subjects, Combined With Preliminary Evaluation of Relative Bioavailability and Effect of Food

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BIBB 1464 MS tablet
Drug: BIBB 1464 MS solution
Drug: BIBB 1464 MS placebo
Other: Standard dinner
First Posted Date
2014-09-01
Last Posted Date
2014-09-01
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
73
Registration Number
NCT02229838

Efficacy and Tolerability of Buscopan Plus in Painful Gastric or Intestinal Spasms

Phase 2
Completed
Conditions
Gastrointestinal Diseases
Interventions
Drug: Placebo
First Posted Date
2014-09-01
Last Posted Date
2014-09-01
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
1637
Registration Number
NCT02229786

Safe Implementation of Thrombolysis in Stroke - Monitoring Study

Completed
Conditions
Stroke
Interventions
First Posted Date
2014-09-01
Last Posted Date
2014-09-01
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
6475
Registration Number
NCT02229812

Antiviral Efficacy, Pharmacokinetics and Safety of BILN 2061 ZW in Patients With Cirrhosis and Chronic Hepatitis C

Phase 2
Completed
Conditions
Liver Cirrhosis
Hepatitis C, Chronic
Interventions
Drug: Placebo
First Posted Date
2014-08-27
Last Posted Date
2014-08-27
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
10
Registration Number
NCT02226939

Relative Bioavailability of Tipranavir (TPV)/Ritonavir (RTV) at Steady State Administered as Oral Solutions vs. Capsules in the Fed and Fasted State in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: TPV solution
Drug: TPV capsule
Other: standard meal
First Posted Date
2014-08-27
Last Posted Date
2014-08-27
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
35
Registration Number
NCT02227017

Mechanism of Dipyridamole Action in Platelets: in Vivo Study With Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2014-08-27
Last Posted Date
2014-08-27
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
15
Registration Number
NCT02226926

Effects of Steady-state Efavirenz 600 mg QD (Sustiva®) on Tipranavir Concentration at Steady-state in Healthy Adult Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2014-08-27
Last Posted Date
2014-08-27
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
34
Registration Number
NCT02226991

Pharmacokinetic Interaction Study of Steady-state Tipranavir/Ritonavir (TPV/r) With Single-dose Valaciclovir (VAL) in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2014-08-27
Last Posted Date
2014-08-27
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
29
Registration Number
NCT02226978

Antiviral Efficacy, Pharmacokinetics and Safety of BILN 2061 ZW in Patients With Chronic Hepatitis C Virus Infection

Phase 1
Completed
Conditions
Hepatitis C, Chronic
Interventions
Drug: BILN 2061 W, medium dose
Drug: BILN 2061 W, high dose
Drug: Placebo
Drug: BILN 2061 W, low dose
First Posted Date
2014-08-27
Last Posted Date
2014-08-27
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
51
Registration Number
NCT02226952
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy